Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer

Alice T. Shaw, MD, PhD
Published: Tuesday, Jan 17, 2017



Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib (Alecensa) as first-line therapy in the treatment of patients with lung cancer.

Though crizotinib (Xalkori) is currently the standard first-line therapy in lung cancer, the J-ALEX study reported out of Japan showed positive results in the alectinib population, suggesting that alectinib may be more effective than crizotinib first-line.

According to Shaw, there is more movement toward using alectinib as the preferred second-generation, second-line ALK inhibitor due to its efficacy and side effect profile. There was a response rate of 50% in crizotinib-resistant patients, an immediate progression-free survival of about 9 months, striking CNS activity, and very manageable side effects of fatigue, edema and muscle aches at grades 1/2.

Currently, there is a global ALEX study that addresses some of the problems of the original study, such as limited ethnicity range.
 


Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib (Alecensa) as first-line therapy in the treatment of patients with lung cancer.

Though crizotinib (Xalkori) is currently the standard first-line therapy in lung cancer, the J-ALEX study reported out of Japan showed positive results in the alectinib population, suggesting that alectinib may be more effective than crizotinib first-line.

According to Shaw, there is more movement toward using alectinib as the preferred second-generation, second-line ALK inhibitor due to its efficacy and side effect profile. There was a response rate of 50% in crizotinib-resistant patients, an immediate progression-free survival of about 9 months, striking CNS activity, and very manageable side effects of fatigue, edema and muscle aches at grades 1/2.

Currently, there is a global ALEX study that addresses some of the problems of the original study, such as limited ethnicity range.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x